Literature DB >> 6302126

Effects of growth hormone replacement therapy on 1,25-dihydroxyvitamin D and calcium metabolism.

S Burstein, I W Chen, R C Tsang.   

Abstract

To elucidate the changes in mineral metabolism and blood concentrations of calciotropic hormones which accompany GH therapy, we studied 12 GH-deficient children for 5 days before and for 1 week after high dose (5 IU/day) GH therapy, and again at 1 month, 3 months, and 1 yr of replacement therapy (0.1 IU/kg to a maximum dose of 2 IU three times weekly). All responded with acceleration of height velocity, and bone ages advanced appropriately. Fasting serum ionized calcium levels did not change: 4.11 +/- 0.06 (SEM) mg/dl before, 4.19 +/- 0.05 for the week of high dose therapy, and 4.20 +/- 0.14 during replacement therapy. Likewise, fasting serum parthormone did not vary: 38.9 +/- 2.6 muleq/ml before to 44.1 +/- 9.2 at 1 yr. Twenty four-hour nephrogenous cyclic AMP (NcAMP) did not vary over the first week (1.2 +/- 0.7 nmol/dl glomerular filtrate before, 1.3 +/- 0.4 after 1 week), but increased to 5.3 +/- 1.9 after 1 yr (alpha less than 0.001). The response of ionized calcium and parathormone to a standardized disodium EDTA infusion of 50 mg/kg also did not change. The mean fasting serum calcitonin level was not different before therapy (29.4 +/- 2.8 pg/ml), after 1 week (21.5 +/- 1.8), or after 1 yr (42.4 +/- 11.0). However, the mean serum 1,25-dihydroxyvitamin D concentration rose from 33.1 +/- 3.3 pg/ml before therapy to 68.3 +/- 12.3 on the seventh day of high dose therapy (alpha less than 0.01), returning to pretherapy values by 1 month. We conclude that high dose GH therapy in GH-deficient children raises 1,25-dihydroxyvitamin D concentration acutely, but that long term, physiological replacement therapy does not cause such an effect. Because NcAMP excretion rose in the absence of an increase in serum parathormone concentration, we conclude that GH sensitizes the kidney to a cAMP-mediated effect of parathormone.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6302126     DOI: 10.1210/jcem-56-6-1246

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Does growth hormone influence the severity of phosphopenic rickets?

Authors:  T Bistritzer; S A Chalew; A Hanukoglu; K M Armour; P J Haney; A A Kowarski
Journal:  Eur J Pediatr       Date:  1990-11       Impact factor: 3.183

2.  Cardiovascular risk in adult hypopituitaric patients with growth hormone deficiency: is there a role for vitamin D?

Authors:  Maria Cristina Savanelli; Elisabetta Scarano; Giovanna Muscogiuri; Luigi Barrea; Laura Vuolo; Manila Rubino; Silvia Savastano; Annamaria Colao; Carolina Di Somma
Journal:  Endocrine       Date:  2015-10-29       Impact factor: 3.633

Review 3.  Renal effects of growth hormone. II. Electrolyte homeostasis and body composition.

Authors:  G D Ogle; A R Rosenberg; G Kainer
Journal:  Pediatr Nephrol       Date:  1992-09       Impact factor: 3.714

Review 4.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 5.  Growth hormone, IGF-I and insulin and their abuse in sport.

Authors:  R I G Holt; P H Sönksen
Journal:  Br J Pharmacol       Date:  2008-03-31       Impact factor: 8.739

Review 6.  Growth hormone replacement therapy for growth hormone-deficient adults.

Authors:  J Powrie; A Weissberger; P Sönksen
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

7.  Serum vitamin D metabolites do not change in response to intravenous injection of thyrotropin releasing hormone (TRH) and growth hormone releasing factor (GHRF 1-44) in children.

Authors:  R Rosskamp; S Issa; W Burmeister
Journal:  J Endocrinol Invest       Date:  1988-01       Impact factor: 4.256

Review 8.  Vitamin D and growth hormone in children: a review of the current scientific knowledge.

Authors:  Susanna Esposito; Alberto Leonardi; Lucia Lanciotti; Marta Cofini; Giulia Muzi; Laura Penta
Journal:  J Transl Med       Date:  2019-03-18       Impact factor: 5.531

Review 9.  Growth hormone doping: a review.

Authors:  Ioulietta Erotokritou-Mulligan; Richard Ig Holt; Peter H Sönksen
Journal:  Open Access J Sports Med       Date:  2011-07-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.